Ocugen Inc at NAI Interactive GCFF Virtual Conference -- Diversified Investing Strategies Transcript
Thank you for joining Ocugen's presentation today. We are a biotechnology company focused on transformative therapies with the potential to cure blindness diseases. We have a very strong pipeline, starting with our breakthrough gene therapy platform, which we call it the Modifier Gene Therapy, which we licensed from Harvard Medical School.
The uniqueness of this platform in ophthalmology area that's -- taking the first product OCU400, it can go after many inherited retinal diseases, which are blindness diseases. For example, if you take a disease called retinitis pigmentosa, which is a significant unmet medical need globally, about 1.5 million patients globally struggle with it. So, that means it's a genetic disease. If your parents have it, most likely you will inherit it.
Currently, there are no approved therapies. There is only one product approved, which addresses about 600 patients in the US. And what we have is a breakthrough and game-changing technology platform. This one product can go after many of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |